Alfred Lee, MD, PhD
Professor of Medicine (Hematology)Cards
About
Research
Publications
2024
In-Human Clinical Experience with Direct Stick Embolization of Low-Flow Vascular Malformations Using an mTOR Inhibitor
Restrepo-Espinosa V, Lee A, Prozora S, Patel P, Nassiri N. In-Human Clinical Experience with Direct Stick Embolization of Low-Flow Vascular Malformations Using an mTOR Inhibitor. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2024, 101997. PMID: 39515753, DOI: 10.1016/j.jvsv.2024.101997.Peer-Reviewed Original ResearchLow-flow vascular malformationsMTOR inhibitorsClinical successVascular malformationsSide effectsLocalized intravascular coagulopathyOral aphthous ulcersKlippel-Trenaunay syndromeLymphatic malformationsVenous malformationsRe-interventionDelayed complicationsNon-syndromicTechnical successAphthous ulcersIntravascular coagulopathyD-dimerEndovascular treatmentSystemic exposureAdjunctive therapySystemic toxicityFrequent bloodMalformationsSelf-limitingMTOR inhibitionUse of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database
Stempel J, Wang R, Lee A, Ma X, Podoltsev N. Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database. Blood 2024, 144: 2319. DOI: 10.1182/blood-2024-202185.Peer-Reviewed Original ResearchHorse anti-thymocyte globulinLow transfusion burdenAcquired aplastic anemiaCalcineurin inhibitor levelsCalcineurin inhibitorsSevere AARed blood cellsEltrombopag therapyTransfusion burdenMedian proportion of daysTransfusion of red blood cellsCalcineurin inhibitor agentsMedian starting doseAnti-thymocyte globulinDiagnosis to initiationTransplant-ineligible patientsBone marrow failureRare autoimmune disorderReduce transfusion requirementsBaseline red blood cellRetrospective cohort studyStudent's t-testProportion of daysBlue Cross Blue ShieldElixhauser comorbidity scoreCost-effectiveness of iptacopan in paroxysmal nocturnal hemoglobinuria
Ito S, Chetlapalli K, Wang D, Potnis K, Richmond R, Krumholz H, Lee A, Cuker A, Goshua G. Cost-effectiveness of iptacopan in paroxysmal nocturnal hemoglobinuria. Blood 2024 PMID: 39374533, DOI: 10.1182/blood.2024025176.Peer-Reviewed Original ResearchStandard-of-careParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitNocturnal hemoglobinuriaComplement-mediated hemolytic anemiaTreating paroxysmal nocturnal hemoglobinuriaComplement C5 inhibitor eculizumabPhase 3 studyQuality-adjusted life expectancyRare blood disorderComprehensive cost-effectiveness analysisProbabilistic sensitivity analysesCost-saving thresholdsC5 inhibitor eculizumabNet monetary benefitPersistent anemiaIptacopanExtravascular hemolysisIntravenous infusionMonotherapyHemolytic anemiaAnemia resolutionC5 inhibitionFDA approvalPrimary outcomePhenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies
Gu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.Peer-Reviewed Original ResearchInherited platelet disordersClinically significant bleedingCases of patientsHeterogeneous group of conditionsGroup of conditionsSignificant bleedingDiagnostic yieldDiagnostic dilemmaPlatelet disordersBleeding disordersEvaluating patientsPatient cohortMolecular pathogenesisMass cytometryHeterogeneous groupPatientsMultimodal approachBleedingImprove patient careDiagnosisDisordersPatient careGenetic sequencesLaboratory testing approachPotential utilityFactor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease.
Allen C, Heskel M, Butt A, Tormey C, Pine A, Lee A, Gautam S. Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease. Acta Haematologica 2024, 1-5. PMID: 39004080, DOI: 10.1159/000540239.Peer-Reviewed Original ResearchISTH DIC scoreFactor VIII levelsArea under the curveDIC scoreLiver diseaseFactor VIIIRetrospective chart review of patientsChart review of patientsCoagulopathy of liver diseaseReview of patientsRetrospective chart reviewCalculate area under the curveReceiver operating characteristic curveMultiple logistic regressionISTH scoreLaboratory parametersClinical challengeClinical utilityPatientsCharacteristic curveLab variablesLogistic regressionLiverDiseaseDiagnostic toolLongitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship Program
Srikumar T, Stempel J, Goldberg S, Podoltsev N, Braun D, Lee A, Sanft T. Longitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship Program. EMJ Oncology 2024, 1: 37-39. DOI: 10.33590/oncolamj/zgwb5064.Peer-Reviewed Original ResearchLongitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program.
Srikumar T, Stempel J, Goldberg S, Podoltsev N, Braun D, Lee A, Sanft T. Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program. Journal Of Clinical Oncology 2024, 42: 9004-9004. DOI: 10.1200/jco.2024.42.16_suppl.9004.Peer-Reviewed Original ResearchNeeds assessmentLongitudinal curriculumPatient Health Questionnaire 2Score of self-efficacyGeneral Self-Efficacy ScaleFellowship programsBaseline needs assessmentFaculty-led sessionsProfessional boundary settingSelf-Efficacy ScaleLevels of depressionProfessional developmentFirst-year fellowsDidactic sessionsPrevent burnoutChi-square testAcademic yearDebriefing sessionsQuestionnaire 2Baseline assessmentSelf-efficacyProfessional development skillsDepressed moodLeadership skillsBurnoutInternational medical graduates (IMG) representation at international oncology conference meetings.
Roy A, Bakouny Z, Dizman N, Ozay Z, Mohan Lal B, Nawfal R, Eid M, El Hajj Chehade R, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall A, Murphy M, Owonikoko T, Lee A, CHOUEIRI T. International medical graduates (IMG) representation at international oncology conference meetings. Journal Of Clinical Oncology 2024, 42: 9000-9000. DOI: 10.1200/jco.2024.42.16_suppl.9000.Peer-Reviewed Original ResearchInternational medical graduatesAmerican medical graduatesASCO Annual MeetingMedical graduatesFaculty rolesMedical schoolsAmerican Society of Clinical Oncology (ASCOUS institutionsInternational oncology meetingsOncology workforceUnder-recognitionOncology meetingsSelection of presentationsAssess factorsMultivariate analysisPracticing oncologistsUS-basedASCOConference meetingsAcademic rankOriginal researchHighest proportionPodium presentationsAmerican SocietyUnited StatesCost‐effectiveness of sutimlimab in cold agglutinin disease
Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost‐effectiveness of sutimlimab in cold agglutinin disease. American Journal Of Hematology 2024, 99: 1475-1484. PMID: 38733355, DOI: 10.1002/ajh.27358.Peer-Reviewed Original ResearchPrimary cold agglutinin diseaseCold agglutinin diseaseStandard-of-careIncremental cost-effectiveness ratioUS willingness-to-pay thresholdRare autoimmune hemolytic anemiaPhase 3 studyWillingness-to-pay thresholdsAutoimmune hemolytic anemiaTime-limited treatmentHuman monoclonal antibodyCold-reactive antibodiesBinding to red blood cellsFollow-up dataCost-effectiveness ratioComplement-mediated hemolysisDeterministic sensitivity analysisHealth resource utilizationProbabilistic sensitivity analysesTransfusion-dependentClinical remissionTransfusion supportImprove quality of lifeRed blood cellsHemolytic anemiaProviding 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment
Butt A, Christian J, Kress A, Lu B, Hurwitz M, Goldberg S, Podoltsev N, Gilkes L, Lee A. Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment. Journal Of Cancer Education 2024, 39: 325-334. PMID: 38430454, DOI: 10.1007/s13187-024-02414-z.Peer-Reviewed Original ResearchFull-time equivalent supportFull-time equivalentAmerican Council for Graduate Medical EducationCore facultyFellowship programsFellowship educationGraduate Medical EducationImprove job satisfactionCF programPotential unintended consequencesMedical educationSalary supportSurvey respondentsIncreased participationMedical oncologyUnintended consequencesSubspecialty fellowshipsIncreased senseSense of commitmentJob satisfactionFellowshipEducationFaculty involvement
Academic Achievements & Community Involvement
Clinical Care
Overview
Alfred Ian Lee, MD, PhD, is Professor of Medicine (Hematology) and Program Director for the hematology/oncology fellowship program. He received his MD/PhD from the Yale School of Medicine in 2004. Dr. Lee completed residency in internal medicine at Brigham & Women’s Hospital, where he served as Chief Medical Resident, followed by a fellowship in hematology/oncology at Dana-Farber Cancer Institute. His primary academic interests are classical hematology, thrombosis, and medical education.
He has received such honors as the Charles W. Bohmfalk Prize for teaching in the basic sciences, the Leah M. Lowenstein Award for excellence in the promotion of humane and egalitarian medical education, the Yale Cancer Center Award for Mentorship Excellence, and the David J. Lefell Prize for Clinical Excellence.
Clinical Specialties
Fact Sheets
Hereditary Hemorrhagic Telangiectasia (HHT)
Learn More on Yale MedicineBleeding Disorders
Learn More on Yale MedicineHodgkin's Lymphoma
Learn More on Yale MedicineAnemia
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
- June 12, 2024
Yale Medical Oncology-Hematology Fellowship Graduation 2024
- May 28, 2024
Annual Fellows Research Day 2024
- May 20, 2024
American Society of Hematology Selects Jennifer Afranie-Sakyi, MD to Receive the 2024 ASH Minority Hematology Fellow Award
- April 15, 2024
Multidisciplinary CMCO Making Strides